<DOC>
	<DOC>NCT02601378</DOC>
	<brief_summary>This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent in patients with metastatic uveal melanoma.</brief_summary>
	<brief_title>A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<criteria>Key Metastatic uveal melanoma (histologically or cytologically confirmed) that is judged to be progressive Willingness to provide newly obtained tumor tissue at baseline and on treatment unless contraindicated by medical risk Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as &gt; 20 mm with conventional techniques or as &gt;10 mm with CT scan. ECOG performance status â‰¤ 1 Key Malignant disease other than that being treated in this study Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Treated brain metastases must have been stable for at least 1 month. Impaired cardiac function or clinically significant cardiac diseases Patients who are receiving treatment with medications that cannot be discontinued prior to study entry and that are considered to be any of the following: known and possible risk for QT prolongation known to be strong inducers or inhibitors of CYP3A4/5 known to be inducers or inhibitors of Pgp known to be substrates of CYP3A4/5 and Pgp with a narrow therapeutic index Patients with abnormal laboratory values as defined by the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Uveal melanoma</keyword>
	<keyword>Metastatic uveal melanoma</keyword>
	<keyword>Phase I</keyword>
	<keyword>LXS196</keyword>
	<keyword>PKC inhibitor</keyword>
	<keyword>dose escalation</keyword>
</DOC>